共 50 条
- [31] Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphomaEJHAEM, 2024, 5 (04): : 896 - 899Alqahtani, Abdullah N. M.Jayne, SandrineAhearne, Matthew J.Trethewey, Christopher S.Duraisingham, Sai S.Lehmann, SusannCowley, Caroline M.Dyer, Martin J. S.Walter, Harriet S.
- [32] OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDYHAEMATOLOGICA, 2019, 104 : 7 - 7Visco, C.Di Rocco, A.Tisi, M.Morello, L.Evangelista, A.Zilioli, V. R.Rusconi, C.Hohaus, S.Sciarra, R.Re, A.Tecchio, C.Chiappella, A.Niebla, A. M.McCulloch, R.Gini, G.Perrone, T.Nassi, L.Pennese, E.Stefani, P. M.Cox, M. C.Bozzoli, V.Fabbri, A.Polli, V.Ferrero, S.De Celis, I. A.Sica, A.Arcaini, L.Balzarotti, M.Rule, S.Vitolo, U.
- [33] Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experienceCANCER MEDICINE, 2019, 8 (16): : 6860 - 6870Jeon, Young-WooYoon, SeugyunMin, Gi JunePark, Sung-SooPark, SilviaYoon, Jae-HoLee, Sung-EunCho, Byung-SikEom, Ki-SeongKim, Yoo-JinKim, Hee-JeLee, SeokMin, Chang-KiLee, Jong WookCho, Seok-Goo
- [34] Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST studyLEUKEMIA, 2021, 35 (03) : 787 - 795Visco, CarloDi Rocco, AliceEvangelista, AndreaQuaglia, Francesca MariaTisi, Maria ChiaraMorello, LuciaZilioli, Vittorio RuggeroRusconi, ChiaraHohaus, StefanSciarra, RobertaRe, AlessandroTecchio, CristinaChiappella, AnnalisaMarin-Niebla, AnaMcCulloch, RoryGini, GuidoPerrone, TommasinaNassi, LucaPennese, ElsaStefani, Piero MariaCox, Maria ChristinaBozzoli, ValentinaFabbri, AlbertoPolli, ValentinaFerrero, SimoneDe Celis, Maria Isabel AlvarezSica, AntonelloPetrucci, LucaArcaini, LucaRule, SimonKrampera, MauroVitolo, UmbertoBalzarotti, Monica
- [35] Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST studyLeukemia, 2021, 35 : 787 - 795Carlo ViscoAlice Di RoccoAndrea EvangelistaFrancesca Maria QuagliaMaria Chiara TisiLucia MorelloVittorio Ruggero ZilioliChiara RusconiStefan HohausRoberta SciarraAlessandro ReCristina TecchioAnnalisa ChiappellaAna Marin-NieblaRory McCullochGuido GiniTommasina PerroneLuca NassiElsa PennesePiero Maria StefaniMaria Christina CoxValentina BozzoliAlberto FabbriValentina PolliSimone FerreroMaria Isabel Alvarez De CelisAntonello SicaLuca PetrucciLuca ArcainiSimon RuleMauro KramperaUmberto VitoloMonica Balzarotti
- [36] Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: Extended follow-up from BRUINBRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 108 - 109Lewis, David JohnWang, Michael L.Shah, Nirav N.Jurczak, WojciechZinzani, Pier LuigiEyre, Toby A.Cheah, Chan Y.Ujjani, Chaitra S.Koh, YoungilIzutzu, KojiGerson, James N.Flinn, IanTessoulin, BenoitAlencar, Alvaro J.Ma, ShuoLech-Maranda, EwaRhodes, JoannaPatel, KrishWoyach, JenniferLamanna, NicoleWang, YucaiTam, ConstantineSeymour, John F.Munir, TalhaNagai, HirokazuHernandez-Ilizaliturri, FranciscoKumar, AnitaZelenetz, AndrewJain, PreteeshNair, BinojTsai, Donald E.Balbas, MinnaWalgren, Richard A.Abada, PaoloWang, ChunxiaoZhao, JunjieMato, Anthony R.
- [37] Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Prior BTK Inhibitor Therapy - a Cohort of the ELM-2 StudyBLOOD, 2024, 144 : 6302 - 6303Cho, Seok-GooKim, Tae MinTaszner, MichalChen, Tsai-YunChoudhry, AafiaUfkin, MelanieUppala, AmulyaSabir, AyeshaMohamed, HeshamAmbati, SrikanthBachy, Emmanuel
- [38] Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell LymphomaBLOOD, 2017, 130Goy, AndreFeldman, Tatyana A.Leslie, Lori A.Panchal, Rima PanchalNyirenda, ThembaSkarbnik, Alan P.Yannotti, KaraZenreich, JoshuaBejot, Colleen M.Stives, SusanChow, Kar FaiBhattacharyya, Pritish K.Yang, XiaoRichards, Ernest
- [39] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)BLOOD, 2020, 136Mehta, AmitkumarTrneny, MarekWalewski, JanRibrag, VincentDartigeas, CarolineChristensen, Jacob HaaberPane, FabrizioRodriguez, GuillermoTaszner, MichalVenugopal, ParameswaranZilioli, Vittorio RuggeroZheng, FredDeMarini, Douglas J.Jiang, WeiZinzani, Pier Luigi
- [40] The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II StudyBLOOD, 2011, 118 (21) : 449 - 450O'Brien, SusanBurger, Jan A.Blum, Kristie A.Furman, Richard R.Coutre, Steven E.Sharman, JeffFlinn, Ian W.Grant, BarbaraHeerema, Nyla A.Johnson, Amy J.Navarro, TashedaHolmgren, EricHedrick, EricByrd, John C.